| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8337991 | The Journal of Steroid Biochemistry and Molecular Biology | 2016 | 30 Pages |
Abstract
Aromatase inhibitors (AIs) are anti-tumor agents used in clinic to treat hormone-dependent breast cancer. AIs block estrogens biosynthesis by inhibiting the enzyme aromatase, preventing tumor progression. Exemestane, a third-generation steroidal AI, belongs to this class of drugs and is currently used in clinic to treat postmenopausal women, due to its high efficacy and good tolerability. Here, its pharmacological and biological aspects as well as its clinical applications and comparison to other endocrine therapeutic agents, are reviewed. It is also focused the benefits and risks of exemestane, drawbacks to be overcome and aspects to be explored.
Keywords
EMAExemestaneIGF-1R3-MADHEASIESΔΨmPDCD4BMDMIRHDACmTORAREGCyPSOFTEGFREORTCHER2EGFNSABPHormone-dependent breast cancerFDAPI3KNF-κB3-methyladenineER+MAPKmicro RNAROSClinical trialsamphiregulinEuropean Medicines agencyAktBone mineral densityTeamEndocrine therapydehydroepiandrosterone sulfateCytochrome P450epidermal growth factorNuclear factor-kappa Bphosphatidylinositide 3-kinaseTextprogrammed cell death 4Endocrine resistanceAromatase inhibitorsmammalian target of rapamycinhistone deacetylaseMitochondrial transmembrane potentialprotein kinase Bmitogen-activated protein kinaseNational Surgical Adjuvant Breast and Bowel ProjectReactive oxygen speciesEstrogen receptorestrogen receptor positiveHuman epidermal growth factor receptor 2insulin-like growth factor 1 receptorEpidermal growth factor receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Ana Filipa Sobral, Cristina Amaral, Georgina Correia-da-Silva, Natércia Teixeira,